Knights of Columbus Asset Advisors LLC Grows Position in Stryker Corporation $SYK

Knights of Columbus Asset Advisors LLC increased its position in Stryker Corporation (NYSE:SYK) by 1.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 33,850 shares of the medical technology company’s stock after purchasing an additional 454 shares during the period. Stryker makes up 0.8% of Knights of Columbus Asset Advisors LLC’s holdings, making the stock its 28th biggest holding. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $13,392,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SYK. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the first quarter worth about $32,000. City Holding Co. grew its position in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after buying an additional 74 shares during the last quarter. Ridgewood Investments LLC increased its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares during the period. Ransom Advisory Ltd bought a new position in shares of Stryker during the first quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker in the first quarter worth $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wells Fargo & Company upped their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target for the company. Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a report on Saturday, September 27th. Finally, Needham & Company LLC raised their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $430.33.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $370.59 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $141.68 billion, a P/E ratio of 49.08, a P/E/G ratio of 2.67 and a beta of 0.94. The business’s 50 day moving average price is $382.81 and its 200-day moving average price is $378.96. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the previous year, the business earned $2.81 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.